Form 4: MPM BioVentures Reduces HOWL Stake

MPM BioVentures, a 10% owner and director, reported the sale of 195,666 shares of Werewolf Therapeutics common stock through pre-scheduled 10b5-1 plans.

Summary

• MPM BioVentures 2014, L.P. and related entities, identified as a 10% owner and director of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• A total of 195,666 shares were sold across three transactions on November 21, 24, and 25, 2025.
• These sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On November 21, 2025, 64,331 shares were sold at a weighted average price of $0.83 per share.
• On November 24, 2025, 88,802 shares were sold at a weighted average price of $0.98 per share.
• On November 25, 2025, 42,533 shares were sold at a weighted average price of $0.92 per share.
• Following these transactions, the reporting persons beneficially own 5,125,770 shares of Werewolf Therapeutics common stock.
• The shares are held indirectly by various MPM entities, including AM LLC, BV 2014, BV 2014(B), AM BV2014, MPM OIF, and UBS Oncology.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a 10% owner and director. Although the sales were pre-scheduled via a 10b5-1 plan, the reduction in stake by a major investor, particularly at current price levels, can be interpreted as a lack of strong conviction or a strategic portfolio rebalancing that reduces exposure to the company, which is generally viewed unfavorably by the market.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating they were scheduled in advance and not necessarily a reaction to recent negative company news.
• The reporting persons still retain a significant beneficial ownership of 5,125,770 shares, demonstrating continued, albeit reduced, investment in the company.

Negatives

• A significant insider, a 10% owner and director, has reduced its stake in the company by selling 195,666 shares.
• The sales occurred at relatively low price points, ranging from $0.80 to $1.03 per share, which could be perceived negatively by the market.

Future Outlook

NA

Management Comments

• Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This filing reflects a routine insider transaction for a biotechnology company. While insider sales can sometimes signal a lack of confidence, the execution under a pre-scheduled 10b5-1 plan is common for large institutional investors managing their portfolio exposure, especially in the volatile biotech sector where early investors may seek to realize gains or rebalance.

Related Party Transactions

• The transactions involve MPM BioVentures 2014, L.P. and several related entities (MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC, MPM Asset Management LLC, MPM Oncology Innovations Fund, L.P., UBS Oncology Impact Fund L.P.) which are all part of the broader MPM BioImpact network.
• Ansbert Gadicke, a managing director and managing partner across these entities, is linked to the beneficial ownership and the signing of the filing.
• These entities collectively act as a 10% owner and director of Werewolf Therapeutics, Inc., making the sales related party transactions in the context of insider reporting.

Stakeholder Impact

• Shareholders: May view the insider selling negatively, potentially leading to downward pressure on the stock price due to perceived lack of confidence from a major investor.
• Company Management: The sales by a director and 10% owner could raise questions about the long-term outlook or valuation from other investors.

Key Dates

Recommendation

While the insider selling by a 10% owner and director is a negative signal, the transactions were executed under a pre-established 10b5-1 plan, suggesting a planned portfolio adjustment rather than an immediate reaction to new adverse information. Given the lack of other specific company news in this filing, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for more comprehensive insights before making a 'buy' or 'sell' decision.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Sale, Form 4, Beneficial Ownership, 10b5-1 Plan, Equity Transaction, Biotechnology, Pharmaceuticals